文献速递胸部肿瘤

局部晚期非小细胞肺癌患者预防性颅脑照射与观察比较:NRG肿瘤/RTOG 0214三期随机临床试验长期更新

Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

NRG肿瘤/RTOG 0214三期随机试验在美国、加拿大及国际291家机构纳入340例III期非小细胞肺癌患者,随机接受预防性颅脑照射(PCI)或观察。中位随访2.1年(存活患者9.2年)显示,PCI未显著改善总生存(HR 0.82,95%CI 0.63-1.06,P=0.12),但显著改善无病生存(HR 0.76,95%CI 0.59-0.97,P=0.03)并降低脑转移发生率(HR 0.43,95%CI 0.24-0.77,P=0.003)。

要点

  • PCI未显著改善III期非小细胞肺癌总生存(HR 0.82,95%CI 0.63-1.06,P=0.12)。
  • PCI显著改善无病生存(HR 0.76,95%CI 0.59-0.97,P=0.03)。
  • PCI显著降低脑转移发生率(HR 0.43,95%CI 0.24-0.77,P=0.003),5年和10年脑转移率16.7% vs 28.3%。

核心结论

  • 在III期局部晚期非小细胞肺癌且治疗后无疾病进展的患者中,PCI降低了5年和10年脑转移率并改善了5年和10年无病生存,但未改善总生存。
  • 本研究虽未达到主要终点,但长期结果揭示了诸多重要发现,将有益于未来试验。
  • 识别合适的患者人群和安全干预措施至关重要。

研究设计与样本

  • NRG肿瘤/RTOG 0214是一项随机三期临床试验,在美国、加拿大及国际291家机构开展。
  • 纳入III期非小细胞肺癌患者,按分期(IIIA vs IIIB)、组织学特征(非鳞癌 vs 鳞癌)和治疗(无手术 vs 手术)分层。
  • 共356例患者入组,16例不符合条件,最终340例随机分配至观察组或PCI组。

主要发现

  • 340例参与者平均(SD)年龄61岁,男性213例,女性127例。
  • 全组中位随访时间2.1年,存活患者中位随访时间9.2年。
  • PCI组总生存未显著优于观察组(HR 0.82;95%CI 0.63-1.06;P=0.12;5年和10年生存率分别为24.7%和17.6% vs 26.0%和13.3%)。
  • PCI组无病生存显著优于观察组(HR 0.76;95%CI 0.59-0.97;P=0.03;5年和10年无病生存率分别为19.0%和12.6% vs 16.1%和7.5%)。
  • PCI组脑转移发生率显著低于观察组(HR 0.43;95%CI 0.24-0.77;P=0.003;5年和10年脑转移率分别为16.7% vs 28.3%)。

关键数值与推荐

  • PCI组发生脑转移的可能性比观察组低57%。
  • 年轻患者(<60岁)和非鳞癌患者发生更多脑转移。
  • 多变量分析显示,PCI与脑转移减少和无病生存改善相关,但与总生存改善无关。
  • 非手术组内的多变量分析提示,PCI有效延长总生存、无病生存并减少脑转移。

局限性

  • 本研究未达到主要终点(总生存未显著改善)。
  • 识别合适的患者人群和安全干预措施至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Brain metastasis (BM) rates are high in locally advanced non-small cell lung cancer (LA-NSCLC), approaching rates seen in small cell lung cancer, where prophylactic cranial irradiation (PCI) is standard of care. Although PCI decreases the incidence of BM in LA-NSCLC, a survival advantage has not yet been shown. OBJECTIVE: To determine if PCI improves survival in LA-NSCLC. DESIGN, SETTING, AND PARTICIPANTS: Radiation Therapy Oncology Group (RTOG) 0214 was a randomized phase 3 clinical trial in stage III NSCLC stratified by stage (IIIA vs IIIB), histologic characteristics (nonsquamous vs squamous) and therapy (no surgery vs surgery). The study took place at 291 institutions in the United States, Canada, and internationally. Of 356 patients with stage III NSCLC entered onto this study, 16 were ineligible; therefore, 340 patients were randomized. INTERVENTION FOR CLINICAL TRIALS: Observation vs PCI. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS). The secondary end points were disease-free survival (DFS) and incidence of BM. RESULTS: Of the 340 total participants, mean (SD) age was 61 years; 213 of the participants were men and 127 were women. The median follow-up time was 2.1 years for all patients, and 9.2 years for living patients. The OS for PCI was not significantly better than observation (hazard ratio [HR], 0.82; 95% CI, 0.63-1.06; P = .12; 5- and 10-year rates, 24.7% and 17.6% vs 26.0% and 13.3%, respectively), while the DFS (HR, 0.76; 95% CI, 0.59-0.97; P = .03; 5- and 10-year rates, 19.0% and 12.6% vs 16.1% and 7.5% for PCI vs observation) and BM (HR, 0.43; 95% CI, 0.24-0.77; P = .003; 5- and 10-year rates, 16.7% vs 28.3% for PCI vs observation) were significantly different. Patients in the PCI arm were 57% less likely to develop BM than those in the observation arm. Younger patients (<60 years) and patients with nonsquamous disease developed more BM. On multivariable analysis, PCI was associated with decreased BM and improved DFS, but not improved OS. Multivariable analysis within the nonsurgical arm suggests that PCI effectively prolongs OS, DFS, and BM. CONCLUSIONS AND RELEVANCE: In patients with stage III LA-NSCLC without progression of disease after therapy, PCI decreased the 5- and 10-year rate of BM and improved 5- and 10-year DFS, but did not improve OS. Although this study did not meet its primary end point, the long-term results reveal many important findings that will benefit future trials. Identifying the appropriate patient population and a safe intervention is critical. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00048997.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Sun A, Hu C, Wong SJ, et al. Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30869743. doi:10.1001/jamaoncol.2018.7220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。